What Are The Recommended Parameters For Pdl And Nd:yag Lasers In Treating Striae Rubra? Start With Conservative Settings

For early red stretch marks, the usual starting parameters are a 585 nm PDL with a 10 mm spot, approximately 450 microseconds, and fluence no higher than 4 J/cm², or a long-pulsed 1064 nm Nd:YAG laser with a 2.5 mm spot, 80–100 J/cm², 15–20 ms pulse delay, and 2 Hz repetition rate. These settings are protocol-level recommendations, not universal prescriptions: treatment must be adjusted for skin phototype, lesion thickness, device design, cooling, and the tissue response.

The central principle is conservative vascular treatment. Striae rubra contain dilated vessels and increased erythema, so vascular lasers can reduce redness while their thermal effects may support collagen remodeling; higher fluence does not necessarily improve results and can increase adverse effects.

Why Laser Selection Matters

Striae rubra are primarily vascular lesions

Early stretch marks are characterized by erythema, vascular dilation, and inflammatory changes in the upper reticular dermis. This makes hemoglobin-targeting devices more appropriate than treatments designed primarily for mature, white atrophic scars.

The treatment goal is twofold

PDL and long-pulsed Nd:YAG lasers aim to reduce visible redness by treating dermal microvasculature. The delivered thermal energy may also encourage dermal collagen remodeling and improve the early lesion’s texture.

Stage determines the appropriate technology

Vascular lasers are best suited to striae rubra, while chronic striae alba generally require fractional non-ablative or ablative resurfacing approaches. A vascular laser should not be expected to correct the hypopigmentation and atrophy of mature white stretch marks by itself.

Recommended PDL Parameters

Wavelength and spot size

A 585 nm PDL is commonly configured with a 10 mm spot size for striae rubra. Broader spot sizes in the approximate 7–10 mm range are also used in vascular protocols, depending on the device and treatment area.

Pulse duration

A pulse duration of approximately 450 microseconds is the protocol described for a 585 nm PDL. The duration should remain appropriate for the target vessel size and the specific laser’s pulse-delivery characteristics.

Fluence

Use a conservative fluence of 4 J/cm² or less. Clinical benefit does not necessarily increase when fluence is pushed higher, whereas the risks of blistering, prolonged inflammation, pigmentary alteration, and scarring may increase.

Skin-type considerations

For darker skin types, clinicians generally select the lower end of the fluence range and use careful epidermal protection. PDL treatment commonly requires only one to two sessions in some early lesions, but the number of sessions depends on the response and the patient’s risk profile.

Recommended Long-Pulsed 1064 nm Nd:YAG Parameters

Spot size

The referenced protocol uses a 2.5 mm spot size. This smaller spot supports concentrated delivery to deeper dermal vessels, but it also increases the importance of avoiding excessive overlap and monitoring the endpoint.

Fluence

A typical protocol range is 80–100 J/cm². The lower end, around 80 J/cm², may be a more conservative starting point, particularly when treating patients with higher pigmentary risk or when the device produces substantial thermal accumulation.

Pulse timing and repetition

Use a 15–20 ms pulse delay and a repetition rate of approximately 2 Hz, consistent with the cited protocol. Exact pulse duration and timing terminology can vary between manufacturers, so the device manual must be reconciled with the clinical protocol.

Cooling

Use forced cold-air cooling or contact cooling throughout treatment. Cooling improves comfort and helps protect the epidermis, which is especially important when using the relatively high fluences associated with long-pulsed 1064 nm Nd:YAG treatment.

How to Choose Between PDL and Nd:YAG

Choose PDL when superficial redness is the dominant concern

PDL directly targets oxyhemoglobin and is generally the more intuitive option when the principal visible feature is superficial erythema. The 585–595 nm range is commonly used for vascular redness, with conservative fluences around 2–4 J/cm² and larger spot sizes.

Consider Nd:YAG when deeper vascular targeting is desired

The 1064 nm wavelength penetrates more deeply and can target vascular structures beneath the superficial epidermis. Its thermal effect may also contribute to collagen remodeling, although treatment must be controlled carefully because the higher fluence range carries greater thermal risk.

Base the decision on the lesion, not the device alone

Color, vessel depth, skin phototype, lesion age, and the patient’s tolerance all influence device selection. The most technically advanced laser is not automatically the best choice if its depth and energy profile do not match the lesion.

Understanding the Trade-offs

Higher energy is not automatically better

For PDL, increasing fluence above approximately 4 J/cm² has not been established by the supplied protocol as a way to improve efficacy. More energy can instead increase the likelihood of purpura, burns, prolonged erythema, and post-inflammatory hyperpigmentation.

Nd:YAG treatment has a narrower thermal safety margin

Long-pulsed Nd:YAG treatment uses substantially higher fluence than PDL. This can support deeper treatment, but it makes cooling, pulse spacing, overlap control, and conservative escalation essential.

Pigmentary risk must be taken seriously

Patients with darker skin types have a greater risk of post-inflammatory hyperpigmentation after vascular laser treatment. Lower fluences, appropriate cooling, cautious test spots, and adequate intervals between treatments are important risk-management measures.

Expectations should remain realistic

Laser treatment can reduce erythema and may improve texture, but it does not reliably erase stretch marks. Across stretch-mark treatments generally, improvement is often partial, and the clinical result depends strongly on lesion stage and baseline atrophy.

Protocols cannot be transferred blindly between devices

A fluence value is meaningful only in the context of spot size, pulse duration, beam profile, cooling, and the specific manufacturer’s system. Parameters reported for facial telangiectasias, for example, should not be transferred directly to stretch marks without clinical justification.

How to Apply This to Treatment Planning

The following ranges should be treated as clinician-supervised starting points rather than self-treatment instructions:

If your primary focus is reducing early redness: Consider a 585–595 nm PDL using a 7–10 mm spot, approximately 2–4 J/cm², and for the cited 585 nm protocol, around 450 microseconds.
If your primary focus is deeper vascular treatment and dermal heating: Consider a long-pulsed 1064 nm Nd:YAG protocol using a 2.5 mm spot, 80–100 J/cm², a 15–20 ms pulse delay, and 2 Hz with continuous cooling.
If your primary focus is minimizing pigmentary or thermal complications: Begin conservatively, use the lowest effective fluence, apply active cooling, avoid excessive overlap, and adjust treatment for skin phototype.
If your primary focus is treating mature white stretch marks: Do not rely on vascular lasers alone; evaluate fractional non-ablative or ablative resurfacing options instead.

The safest effective protocol is the one that matches the lesion’s stage and vascular depth while producing clinical improvement without excessive epidermal or pigmentary injury.

Summary Table:

Laser Type	Wavelength	Spot Size	Pulse Duration	Fluence	Repetition Rate
PDL	585 nm	10 mm	~450 μs	≤4 J/cm²	-
Nd:YAG	1064 nm	2.5 mm	15–20 ms	80–100 J/cm²	2 Hz

Upgrade your clinic's aesthetic capabilities with BELIS's advanced laser systems. Our professional-grade devices, including PDL and Nd:YAG lasers, are designed for safe, effective treatment of vascular lesions like striae rubra. Trusted by clinics worldwide, BELIS offers reliable technology, comprehensive training, and dedicated support. Contact us today to learn how our solutions can enhance your practice and patient outcomes.